Get started

Financials · FLGT

Fulgent Genetics Inc. (FLGT) financials

For the twelve months ended Sep 30, 2026, Fulgent Genetics Inc. reported $330.27M of revenue and -$91.56M of net income.

Revenue, TTM
$330.27M
Revenue growth, YoY
+4.7%
Net income, TTM
-$91.56M
Net margin
-27.7%
Free cash flow, TTM
-$1.40M
EPS, diluted, TTM
-$3.10
Cash
$86.79M
P/S
2.21
Market cap
$730.6M
Annual revenue$322.67M
FY2016FY2025
Annual net income-$60.51M
FY2016FY2025
Annual free cash flow-$124.21M
FY2016FY2025

FLGT revenue and earnings growth

FLGT revenueQ3 2026$90.41M

Quarter YoY
+7.5%
QoQ
+5.9%
FY YoY
+13.8%
5Y CAGR
-5.2%
10Y CAGR
+42.2%

FLGT revenue was $90.41M in fiscal Q3 2026 (ended Sep 30, 2026), up 7.5% from a year earlier and up 5.9% from the prior quarter. For the full fiscal 2025 it was $322.67M, up 13.8% from fiscal 2024. Compound annual growth was -5.2% over 5 years and +42.2% over 10 years. It rose in 7 of the last 10 fiscal years.

FLGT net incomeQ3 2026-$13.15M

FLGT net income was -$13.15M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$6.61M a year earlier. For the full fiscal 2025 it was -$60.51M, compared with -$42.71M in fiscal 2024.

FLGT EPSQ3 2026-$0.48

FLGT diluted EPS was -$0.48 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.21 a year earlier. For the full fiscal 2025 it was -$1.97, compared with -$1.41 in fiscal 2024.

FLGT free cash flowQ3 2026$107.44M

Quarter YoY
21x

FLGT free cash flow was $107.44M in fiscal Q3 2026 (ended Sep 30, 2026), up about 21-fold from a year earlier. For the full fiscal 2025 it was -$124.21M, compared with -$19.25M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$322.67M$283.47M$289.21M$618.97M$992.58M$421.71M$32.53M$21.35M$18.73M$18.28M
Cost of revenue$191.80M$176.25M$184.76M$252.07M$215.53M$89.81M$14.11M$10.70M$8.55M$6.72M
Gross profit$130.88M$107.22M$104.46M$366.90M$777.05M$331.90M$18.42M$10.65M$10.18M$11.55M
Research and development$53.91M$48.82M$41.44M$28.91M$24.22M$11.58M$6.54M$5.53M$4.22M$3.56M
Selling, general and admin$116.66M$88.11M$89.00M$111.07M$50.73M$15.21M$6.41M$5.54M$5.23M$4.61M
Operating income-$91.10M-$73.92M-$195.53M$178.53M$675.95M$290.16M-$428.0K-$5.07M-$3.48M$918.0K
Interest expense$75.0K-$170.0K$488.0K$1.01M$117.0K$20.0K----
Pre-tax income-$70.03M-$51.96M-$174.09M$184.03M$677.30M$291.68M$409.0K-$4.64M-$3.00M-$4.47M
Income tax-$8.39M-$8.14M$1.15M$42.10M$174.79M$72.53M$43.0K$36.0K-$1.01M$920.0K
Net income-$60.51M-$42.71M-$167.82M$143.40M$507.36M$214.31M-$411.0K-$5.61M-$2.51M-$5.35M
EPS, basic-$1.97-$1.41-$5.63$4.76$17.25$9.44-$0.02-$0.31-$0.14-
EPS, diluted-$1.97-$1.41-$5.63$4.63$16.38$8.91-$0.02-$0.31-$0.14-
Diluted shares30.8M30.2M29.8M31.0M31.0M24.1M18.7M18.0M17.7M13.7M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$50.19M$55.28M$97.47M$79.51M$164.89M$87.43M$11.96M$6.74M$6.49M$7.90M
Receivables$84.76M$69.02M$51.13M$52.75M$138.91M$183.86M$6.55M$5.95M$4.00M$4.36M
Current assets$550.49M$353.57M$507.85M$627.87M$611.96M$523.62M$37.08M$39.54M$32.93M$26.14M
Goodwill$25.08M$22.05M$22.05M$143.03M$50.90M-----
Total assets$1.21B$1.22B$1.24B$1.39B$1.28B$700.46M$88.76M$53.90M$57.18M$58.04M
Current liabilities$84.97M$72.90M$73.02M$88.11M$105.31M$130.12M$3.72M$2.74M$3.00M$3.32M
Total liabilities$106.81M$90.81M$102.04M$116.18M$112.84M$131.07M$5.98M$2.75M$3.01M$3.56M
Shareholders' equity$1.11B$1.13B$1.13B$1.27B$1.17B$569.39M$82.78M$51.15M$54.18M$54.48M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$101.64M$21.06M$27.00M$253.52M$538.58M$140.63M$5.52M-$675.0K$1.33M$4.41M
Capital expenditures$22.57M$40.31M$22.21M$18.77M$23.81M$35.13M$1.18M$2.32M$2.90M$3.79M
Free cash flow-$124.21M-$19.25M$4.80M$234.75M$514.76M$105.50M$4.33M-$3.00M-$1.56M$617.0K
Investing cash flow$111.37M-$58.35M$38.90M-$261.31M-$546.55M-$326.44M-$29.05M$950.0K-$2.05M-$42.80M
Financing cash flow-$14.79M-$4.85M-$47.78M-$77.14M$85.41M$261.25M$28.77M$15.0K-$770.0K$45.79M
Share repurchases$10.88M$225.0K$25.06M$74.34M-$62.0K$21.0K---
Stock-based compensation$39.58M$44.48M$42.92M$32.64M$15.88M$8.16M$3.21M$2.30M$2.12M$4.65M
Depreciation and amortization$24.12M$24.93M$26.14M$32.66M$11.00M$2.96M$2.11M-$1.73M$1.17M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY13.8%-2.0%-53.3%-37.6%135.4%1196.5%52.3%14.0%2.5%90.9%
Net income growth, YoY----71.7%136.7%-----
EPS growth, YoY----71.7%83.8%-----
Gross margin40.6%37.8%36.1%59.3%78.3%78.7%56.6%49.9%54.3%63.2%
Operating margin-28.2%-26.1%-67.6%28.8%68.1%68.8%-1.3%-23.7%-18.6%5.0%
Net margin-18.8%-15.1%-58.0%23.2%51.1%50.8%-1.3%-26.3%-13.4%-29.3%
Free cash flow margin-38.5%-6.8%1.7%37.9%51.9%25.0%13.3%-14.0%-8.4%3.4%
Return on equity-5.4%-3.8%-14.8%11.3%43.5%37.6%-0.5%-11.0%-4.6%-9.8%
Return on assets-5.0%-3.5%-13.6%10.3%39.7%30.6%-0.5%-10.4%-4.4%-9.2%
Current ratio6.484.856.967.135.814.029.9614.4410.987.88

Source: XBRL data Fulgent Genetics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

FLGT peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
FLGT$330.27M+4.7%-$91.56M-27.7%$730.6M
DGX$11.84B+9.1%$1.13B9.5%$28.57B
MYGN$803.60M-2.6%-$129.10M-16.1%$549.0M
NTRA$2.91B+37.4%-$164.71M-5.7%$46.46B
WGS$460.78M+14.6%-$111.05M-24.1%$1.96B

FLGT FAQ

9 questions
  • What is FLGT revenue?
    Fulgent Genetics Inc. (FLGT) reported $330.27M of revenue for the twelve months ended Sep 30, 2026. That is up 4.7% from the year before. Revenue for fiscal 2025 was $322.67M.
  • Is FLGT profitable?
    No. Fulgent Genetics Inc. reported a net loss of $91.56M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does FLGT have?
    Fulgent Genetics Inc. reported $86.79M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is FLGT revenue growing?
    Fulgent Genetics Inc.'s revenue changed +13.8% in fiscal 2025, to $322.67M. Its compound annual growth rate was -5.2% over 5 years and +42.2% over 10 years.
  • What is FLGT gross margin?
    Fulgent Genetics Inc.'s gross profit was $111.70M on $330.27M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 33.8%.
  • What is FLGT free cash flow?
    Fulgent Genetics Inc. generated -$1.40M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $14.43M less capital expenditures.
  • What is FLGT earnings per share?
    Diluted earnings per share were -$3.10 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did FLGT last report financial results?
    The latest statements here come from Fulgent Genetics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this FLGT financial data come from?
    Quantisnow builds these statements from the structured XBRL data Fulgent Genetics Inc. files with the SEC. It is provided for information only and is not investment advice.